Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC as Adjuvant Therapy in ACLF
NCT05089981Unknown
- Sponsor
- Aga Khan University
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in acute-on-chronic liver failure (ACLF) comparing NAC group with Placebo group (2 arms). Primary endpoint: Efficacy and safety of NAC in the improvement of ACLF at 72 hours. Status: unknown.
02
Drugs
acetylcysteine
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT05089981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089981.